Immunoassay Market

Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Rapid Tests), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Blood Banks) & Region - Global Forecast to 2028

Report Code: MD 4751 Oct, 2023, by marketsandmarkets.com

The global immunoassay market in terms of revenue was estimated to be worth $35.0 billion in 2023 and is poised to reach $46.7 billion by 2028, growing at a CAGR of 5.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is driven by the rising incidence of chronic and infectious diseases, and growth in the biotechnology and biopharmaceutical industries. On the other hand, stringent requirements for approval of immunoassay instruments and consumables are expected to restrain the growth of this market to a certain extent.

Attractive Opportunities in the Immunoassay Market

Immunoassay Market

To know about the assumptions considered for the study, Request for Free Sample Report

Immunoassay Market

Immunoassay Market Dynamics

DRIVER: Growth in the biotechnology and biopharmaceutical industries

The demand for immunoassay instruments and consumables is considerably high in the bio-pharma industries. Hence, growth in these industries is anticipated to drive the demand for immunoassay products during the forecast period. In these industries, the increase in the demand from end users has provided an opportunity to various companies to launch new products in the market, hence enabling product innovation. Besides, immunoassays are applied at many stages in biopharma and biotechnology industries—from product development and manufacturing to quality control—in production.

The biotechnology and pharmaceutical sectors have experienced various developments and changes in the past few years. Immunoassays have an extensive role in drug discovery and monitoring; ELISA and radioimmunoassays are utilized for the immunogenicity assessment of certain biologics such as adalimumab and infliximab.

In the past few years, many healthcare start-ups have emerged that offer diagnostic assays such as immunoassays and the related kits & reagents.

  • In December 2021, a Canadian start-up company, Nomic (Canada), collected over USD 17 million for its automated, high-throughput ELISA platform.
  • In September 2021, Biotech start-up company, immunitoAI Private Limited (India) raised over USD 1 million in seed funding.

These developments and the emerging biotech and diagnostic companies would fuel the growth of the market.

RESTRAINT: Stringent requirements for the approval of immunoassay instruments and consumables

Regulatory authorities have laid down stringent regulations for the approval and commercialization of immunoassay instruments and consumables. The US FDA, the European Medical Device Directives (CE), and the National Medical Products Association (NMPA, formerly the China Food and Drug Administration or CFDA) are responsible for the approval of immunoassay instruments and consumables in the US, Europe, and China.

US

The FDA regulates the design and manufacturing of immunoassay instruments and consumables in the US. The design and construction of these instruments, which are considered Class II medical devices in the US, should adhere to precisely documented processes. Their performance should meet stringent documentation, development testing, production testing, and field maintenance requirements. The products should also include comprehensive self-test and fault indication capabilities. Manufacturers of immunoassay instruments and consumables must also submit a premarket notification or 510(k) to prove substantial equivalence to a legally marketed device. The stringent and long process for obtaining regulatory approval can hamper the rate product launches and approvals in the market.

OPPORTUNITY: Growth opportunities in emerging economies

Developing economies such as India, China, Taiwan, South Korea, South Africa, Brazil, and Turkey, are expected to offer growth opportunities for major players operating in the market. This can be attributed to the growing geriatric population, increasing prevalence of chronic and infectious diseases, improvement in the healthcare infrastructure, and increasing disposable income in these countries. Some of the major statistics related to the rising geriatric population and growing disease burden in developing economies have been mentioned below:

  • According to the National Development Council, the geriatric population of Taiwan will reach 19.9% in 2025, 23.9% in 2030, and 27.3% in 2035.
  • According to the 13th Five-year Plan on Development of Undertakings on Ageing and Old Age Support System by the State Council, the geriatric population of China will reach up to 255 million by 2020. The official website of the Central Government of China in 2017 highlighted the rise of the old-age dependency ratio up to 28%.

The Asia Pacific has emerged as a business-friendly hub due to relatively less stringent regulations and data requirements. This encourages biopharmaceutical and pharmaceutical companies to outsource their drug discovery activities to the APAC. Asian markets, especially China and India, have many contract research organizations (CROs) that offer drug discovery services for pharmaceutical and biotechnology companies.

CHALLENGE: Design challenges, complexities, and the quality of antibodies

The validation of immunoassays is a complex process that relies on sensitivity and specificity. The diagnosis is often misinterpreted due to false negatives and false positives. As a result, technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as chemiluminescent immunoassays and multiplex flow immunoassays (MFI).

Laboratory space also needs to be reconfigured to meet the requirements of conducting specific immunoassay tests used for pathogen detection to avoid cross-contamination and ensure efficient time management. This results in considerable cost escalation to maintain and operate advanced immunoassay instruments, particularly those capable of handling a single sample type.

Immunoassay Market Ecosystem /Market Map

Immunoassay Market Ecosystem

In 2022, ELISA accounted for the largest share in the immunoassay industry, by technology.

The immunoassay market is segmented into ELISA, Chemiluminescence Immunoassay (CLIA), Immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other technologies. ELISA accounted for the largest share of the market in 2022 by technology. Increasing use of ELISA tests for the diagnosis of chronic conditions such as cancer and infectious diseases detection is expected to contribute to the significant share of the technology segment.

In 2022, blood specimen segment accounted for the largest share in the immunoassay industry, by specimen.

Based on specimens, the immunoassay market is segmented into blood, urine, saliva, and other specimens. In 2022, blood specimens accounted for the largest share of the market, by specimen. The detection of various medical conditions is possible through blood samples as compared to other specimens such as urine or saliva. Moreover, with a rise in blood donation activities, the segment is expected to witness considerable growth during the forecast period.

In 2022, hospitals & clinics accounted for the largest share in the immunoassay industry, by end user.

The immunoassay market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies, clinical laboratories, and CROs, blood banks, research & academic laboratories, and home care settings. Hospitals & clinics accounted for the largest share of the market by end user. The share of the end user segment is owing to the rise in prevalence of conditions such as cancer and infectious diseases, which require frequent visits to the hospitals for diagnostic checkups.

In 2022, North America accounted for the largest share of the immunoassay industry.

The global immunoassay market is segmented into five major regions: North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America. North America accounted for the largest share of the market in 2022. The availability of government funds, the increasing use of immunoassays in clinical diagnostics, and the presence of key players in the region contribute to this regional segment’s large share.

Immunoassay Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), and Thermo Fisher Scientific, Inc. (US). These players’ market leadership is due to their broad product portfolios and vast global footprint. These dominant market players have advantages, including strong research and development budgets, better marketing and distribution networks, and established brand recognition.

Scope of the Immunoassay Industry:

Report Metric

Details

Market Revenue in 2023

$35.0 billion

Estimated Value by 2028

$46.7 billion

Revenue Rate

Poised to grow at a CAGR of 5.9%

Market Driver

Growth in the biotechnology and biopharmaceutical industries

Market Opportunity

Growth opportunities in emerging economies

This report categorizes the immunoassay market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • Reagents & Kits
    • ELISA Reagents & Kits
    • CLIA Reagents & Kits
    • IFA Reagents & Kits
    • Rapid Test Reagent & Kits
    • ELISpot Reagent & Kits
    • Western Blot Reagent & Kits
    • Other Reagents & Kits
  • Analyzers
    • By Type
      • Open-ended Systems
      • Closed-ended Systems
    • By Purchase Mode
      • Rental Purchase
      • Outright Purchase

By Technology

  • ELISA
  • Chemiluminescence Immunoassay (CLIA)
  • Immunofluorescence assay (IFA)
  • Rapid Tests
  • ELISpot
  • Western Blotting
  • Other Technologies

By Specimen

  • Blood
  • Saliva
  • Urine
  • Other Specimens

By Application

  • Infectious Diseases
  • Endocrinology
  • Oncology
  • Bone & Mineral Disorders
  • Cardiology
  • Blood Screening
  • Autoimmune Disorders
  • Allergy Diagnostics
  • Toxicology
  • Newborn Screening
  • Other Applications

By End User

  • Hospitals & Clinics
  • Clinical Laboratories
  • Pharmaceutical & Biotechnology Companies and CROs
  • Blood Banks
  • Research & Academic Laboratories
  • Home Care Settings

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments of Immunoassay Industry

  • In August 2023, Abbott received FDA approval for its Alinity h-series hematology system, enabling laboratories nationwide to run complete blood counts (CBC).
  • In July 2023, Siemens received FDA clearance and launched its Atellica CI Analyzer for immunoassay and clinical chemistry in the world’s major markets.
  • In June 2023, DiaSorin launched its CE marked LIAISON B·R·A·H·M·S MR-proADM assay to be used for the diagnosis of conditions, such as kidney diseases, sepsis, septic shock, lower respiratory and urinary tract infections.
  • In December 2022, QuidelOrtho received approval from Health Canada for use of the Quidel TriageTrue High-Sensitivity Troponin I (hsTnl) Test to aid in the diagnosis of myocardial infarction.
  • In October 2022, Roche received U.S. FDA granted Emergency Use Authorization (EUA) for its cobas MPXV for use on the cobas 6800/8800 immunoassay Systems.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 40)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
    1.3 INCLUSIONS & EXCLUSIONS 
    1.4 MARKET SCOPE 
           1.4.1 MARKETS COVERED
                    FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION
           1.4.2 REGIONS COVERED
           1.4.3 YEARS CONSIDERED
           1.4.4 CURRENCY CONSIDERED
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
           1.6.1 IMPACT OF RECESSION: IMMUNOASSAY INDUSTRY
 
2 RESEARCH METHODOLOGY (Page No. - 46)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 5 REVENUE SHARE ANALYSIS
          FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
          FIGURE 7 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS 
    2.5 STUDY ASSUMPTIONS 
           2.5.1 MARKET ASSUMPTIONS
           2.5.2 GROWTH RATE ASSUMPTIONS
    2.6 RESEARCH LIMITATIONS 
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
           2.6.2 SCOPE-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET
    2.8 IMPACT OF RECESSION ON IMMUNOASSAY INDUSTRY
 
3 EXECUTIVE SUMMARY (Page No. - 59)
    FIGURE 9 IMMUNOASSAY MARKET SHARE, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
    FIGURE 10 IMMUNOASSAY INDUSTRY, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
    FIGURE 11 IMMUNOASSAY ANALYZERS MARKET, BY SPECIMEN, 2023 VS. 2028 (USD BILLION)
    FIGURE 12 MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
    FIGURE 13 AUTOMATED IMMUNOASSAY ANALYZERS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    FIGURE 14 GEOGRAPHICAL SNAPSHOT: MARKET
 
4 PREMIUM INSIGHTS (Page No. - 65)
    4.1 IMMUNOASSAY MARKET OVERVIEW 
          FIGURE 15 RISING INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
    4.2 NORTH AMERICA: IMMUNOASSAY INDUSTRY,  BY PRODUCT AND COUNTRY (2022) 
          FIGURE 16 REAGENTS & KITS AND US DOMINATED NORTH AMERICAN MARKET IN 2022
    4.3 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY ANALYZERS MARKET,  2023–2028 
          FIGURE 17 CHINA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
    4.4 REGIONAL MIX: AUTOMATED IMMUNOASSAY ANALYZERS MARKET, 2021–2028 
          FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD
    4.5 DEVELOPED VS. EMERGING ECONOMIES:  MARKET, 2023–2028 
          FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 70)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMMUNOASSAY MARKET
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidence of chronic and infectious diseases
                                FIGURE 21 INCREASING INCIDENCES OF DIABETES (IN MILLION)
                               5.2.1.1.1 Growing use of immunoassays in oncology
                                              TABLE 2 GLOBAL INCIDENCE OF MAJOR CANCERS IN MEN, 2020
                                              TABLE 3 GLOBAL INCIDENCE OF MAJOR CANCERS IN WOMEN, 2020
                               5.2.1.1.2 Increasing use of immunoassays in diagnostic applications
                                              TABLE 4 TIME REQUIRED FOR DRUG DETECTION BY URINE TESTING
                               5.2.1.1.3 Growing geriatric population
                                              FIGURE 22 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (IN MILLION)
                    5.2.1.2 Increasing need for blood donations
                    5.2.1.3 Growth in biotechnology & biopharmaceutical industries
                    5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing
                    5.2.1.5 Supportive government regulatory policies and initiatives
                    5.2.1.6 Increased drug abuse and use of cannabis
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent approval criteria for immunoassay instruments and consumables
                    5.2.2.2 Technical problems in immunoassay kits
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing growth opportunities in emerging economies
                    5.2.3.2 Importance of companion diagnostics
                                TABLE 5 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED, 2018–2022
                    5.2.3.3 Development of condition-specific biomarkers and tests
                                TABLE 6 NEW TESTS LAUNCHED BY KEY PLAYERS, 2019–2023
                    5.2.3.4 Integration of microfluidics in immunoassays
                                TABLE 7 LAB-ON-A-CHIP IMMUNOASSAY DEVICES/CHIPS/SYSTEMS OFFERED BY KEY PLAYERS
                    5.2.3.5 Improved immunoassay diagnostic technologies
           5.2.4 CHALLENGES
                    5.2.4.1 Design challenges, complexities, and low quality of antibodies
                    5.2.4.2 Dearth of skilled professionals
                    5.2.4.3 Unfavorable reimbursement scenario
    5.3 REGULATORY ANALYSIS 
           5.3.1 NORTH AMERICA
                    5.3.1.1 US
                                TABLE 8 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
                                FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES
                    5.3.1.2 Canada
                                FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES
           5.3.2 EUROPE
                    TABLE 9 EUROPE: CLASSIFICATION OF IVD DEVICES
                    5.3.2.1 Russia
                                TABLE 10 RUSSIA: CLASSIFICATION OF IVD DEVICES
           5.3.3 ASIA PACIFIC
                    5.3.3.1 Japan
                                FIGURE 25 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
                                TABLE 11 JAPAN: CLASSIFICATION OF IVD REAGENTS
                                TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.3.3.2 China
                                TABLE 13 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.3.3.3 India
                                FIGURE 26 INDIA: REGULATORY PROCESS FOR IVD DEVICES
                    5.3.3.4 Indonesia
                                TABLE 14 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
                    5.3.3.5 South Korea
                                TABLE 15 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.3.4 LATIN AMERICA
                    5.3.4.1 Mexico
                                FIGURE 27 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
                                TABLE 16 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.3.4.2 Brazil
                                FIGURE 28 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
           5.3.5 MIDDLE EAST
                    5.3.5.1 Saudi Arabia
                                TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.3.6 AFRICA
    5.4 TECHNOLOGY ANALYSIS 
          TABLE 18 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES
          TABLE 19 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY INDUSTRY
    5.5 TRADE ANALYSIS 
           5.5.1 TRADE ANALYSIS FOR IMMUNOASSAY PRODUCTS
                    TABLE 20 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
                    TABLE 21 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
    5.6 PATENT ANALYSIS 
    5.7 VALUE CHAIN ANALYSIS 
          FIGURE 29 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.8 SUPPLY CHAIN ANALYSIS 
          FIGURE 30 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.9 ECOSYSTEM/MARKET MAP 
          FIGURE 31 ECOSYSTEM/MARKET MAP: MARKET
           5.9.1 ROLE IN ECOSYSTEM
           5.9.2 KEY PLAYERS IN MARKET
    5.10 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 22 PORTER’S FIVE FORCES
           5.10.1 INTENSITY OF COMPETITIVE RIVALRY
           5.10.2 BARGAINING POWER OF SUPPLIERS
           5.10.3 BARGAINING POWER OF BUYERS
           5.10.4 THREAT OF SUBSTITUTES
           5.10.5 THREAT FROM NEW ENTRANTS
    5.11 KEY CONFERENCES & EVENTS IN 2023–2024 
           TABLE 23 KEY CONFERENCES & EVENTS IN 2023–2024
    5.12 PRICING ANALYSIS 
           TABLE 24 PRICE RANGE FOR IMMUNOASSAY PRODUCTS
    5.13 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
                     TABLE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
           5.13.2 BUYING CRITERIA
                     FIGURE 33 KEY BUYING CRITERIA FOR TOP END USERS
                     TABLE 26 KEY BUYING CRITERIA, BY TOP END USER
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
 
6 IMMUNOASSAY MARKET TRENDS, BY PRODUCT (Page No. - 108)
    6.1 INTRODUCTION 
          TABLE 27 IMMUNOASSAY INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 REAGENTS & KITS 
          TABLE 28 KEY REAGENTS & KITS AVAILABLE
          TABLE 29 MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 30 MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)
           6.2.1 ELISA REAGENTS & KITS
                    6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment
                                TABLE 31 ELISA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.2 RAPID TEST REAGENTS & KITS
                    6.2.2.1 High demand for rapid test reagents & kits in remote areas for preliminary screening tests to drive segment
                                TABLE 32 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.3 ELISPOT REAGENTS & KITS
                    6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to drive segment
                                TABLE 33 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.4 CLIA REAGENTS & KITS
                    6.2.4.1 Better diagnosis and higher specificity to drive segment
                                TABLE 34 CLIA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.5 IFA REAGENTS & KITS
                    6.2.5.1 Better adaptability in clinical diagnostics and medicine to drive segment
                                TABLE 35 IFA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.6 WESTERN BLOT REAGENTS & KITS
                    6.2.6.1 Western blotting reagents & kits to be considered gold standard for COVID-19 test result validation
                                TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.7 OTHER REAGENTS & KITS
                    TABLE 37 OTHER REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.3 ANALYZERS 
          TABLE 38 KEY ANALYZERS AVAILABLE
          TABLE 39 MARKET FOR ANALYZERS, BY REGION, 2021–2028 (USD MILLION)
           6.3.1 MARKET FOR ANALYZERS, BY TYPE
                    TABLE 40 AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)
                    6.3.1.1 Open-ended systems
                               6.3.1.1.1 Better flexibility and wider availability to drive segment
                                              TABLE 41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    6.3.1.2 Closed-ended systems
                               6.3.1.2.1 Higher precision and better automation to drive segment
                                              TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.3.2 MARKET FOR ANALYZERS, BY PURCHASE MODE
                    TABLE 43 MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                    6.3.2.1 Rental purchase
                               6.3.2.1.1 Increased convenience and lack of liability to drive segment
                                              TABLE 44 RENTAL PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION)
                    6.3.2.2 Outright purchase
                               6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market
                                              TABLE 45 OUTRIGHT PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION)
 
7 IMMUNOASSAY MARKET TRENDS, BY TECHNOLOGY (Page No. - 126)
    7.1 INTRODUCTION 
          TABLE 46 IMMUNOASSAY INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 ELISA 
           7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET
                    TABLE 47 KEY ELISA TECHNOLOGIES AVAILABLE
                    TABLE 48 IMMUNOASSAY ANALYZERS MARKET FOR ELISA, BY REGION, 2021–2028 (USD MILLION)
    7.3 CLIA 
           7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO DRIVE MARKET
                    TABLE 49 IMMUNOASSAY MARKET SHARE FOR CLIA, BY REGION, 2021–2028 (USD MILLION)
    7.4 IFA 
           7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES
                    TABLE 50 AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR IFA, BY REGION, 2021–2028 (USD MILLION)
    7.5 RAPID TESTS 
           7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE MARKET
                    TABLE 51 KEY RAPID TESTS AVAILABLE
                    TABLE 52 MARKET FOR RAPID TESTS, BY REGION, 2021–2028 (USD MILLION)
    7.6 WESTERN BLOTTING 
           7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO DRIVE MARKET
                    TABLE 53 WESTERN BLOTTING SYSTEMS AVAILABLE
                    TABLE 54 IMMUNOASSAY ANALYZERS MARKET FOR WESTERN BLOTTING, BY REGION,  2021–2028 (USD MILLION)
    7.7 ELISPOT 
           7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO DRIVE MARKET
                    TABLE 55 MARKET FOR ELISPOT, BY REGION, 2021–2028 (USD MILLION)
    7.8 OTHER TECHNOLOGIES 
          TABLE 56 MARKET FOR OTHER TECHNOLOGIES, BY REGION,  2021–2028 (USD MILLION)
 
8 IMMUNOASSAY MARKET TRENDS, BY SPECIMEN (Page No. - 136)
    8.1 INTRODUCTION 
          TABLE 57 IMMUNOASSAY INDUSTRY, BY SPECIMEN, 2021–2028 (USD MILLION)
    8.2 BLOOD 
           8.2.1 HIGH RELIABILITY AND ADVANCEMENTS IN HEALTHCARE SYSTEM TO DRIVE MARKET
                    TABLE 58 IMMUNOASSAY MARKET SHARE FOR BLOOD, BY REGION, 2021–2028 (USD MILLION)
    8.3 SALIVA 
           8.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET
                    TABLE 59 AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION)
    8.4 URINE 
           8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO DRIVE MARKET
                    TABLE 60 MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
    8.5 OTHER SPECIMENS 
          TABLE 61 MARKET FOR OTHER SPECIMENS, BY REGION,  2021–2028 (USD MILLION)
 
9 IMMUNOASSAY MARKET TRENDS, BY APPLICATION (Page No. - 142)
    9.1 INTRODUCTION 
          TABLE 62 IMMUNOASSAY INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    9.2 INFECTIOUS DISEASES 
           9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET
                    TABLE 63 MARKET FOR INFECTIOUS DISEASES, BY REGION,  2021–2028 (USD MILLION)
    9.3 ENDOCRINOLOGY 
           9.3.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET
                    TABLE 64 IMMUNOASSAY MARKET SHARE FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.4 CARDIOLOGY 
           9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
                    TABLE 65 KEY PRODUCTS FOR CARDIOLOGY APPLICATIONS
                    TABLE 66 MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.5 AUTOIMMUNE DISORDERS 
           9.5.1 HIGH INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
                    TABLE 67 MARKET FOR AUTOIMMUNE DISORDERS, BY REGION,  2021–2028 (USD MILLION)
    9.6 ALLERGY DIAGNOSTICS 
           9.6.1 GROWING PREVALENCE OF ALLERGIES TO DRIVE MARKET
                    TABLE 68 MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,  2021–2028 (USD MILLION)
    9.7 ONCOLOGY 
           9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO DRIVE MARKET
                    TABLE 69 INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS. 2040 (MILLION)
                    TABLE 70 IMMUNOASSAY ANALYZERS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.8 BONE & MINERAL DISORDERS 
           9.8.1 INCREASING PREVALENCE OF BONE DISEASES TO DRIVE MARKET
                    TABLE 71 KEY PRODUCTS FOR BONE & MINERAL DISORDERS
                    TABLE 72 AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR BONE & MINERAL DISORDERS, BY REGION,  2021–2028 (USD MILLION)
    9.9 DRUG MONITORING AND TESTING 
           9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
                    TABLE 73 KEY PRODUCTS FOR DRUG MONITORING
                    TABLE 74 KEY IMMUNOASSAY PRODUCTS FOR DRUG TESTING
                    TABLE 75 MARKET FOR DRUG MONITORING AND TESTING,  BY REGION, 2021–2028 (USD MILLION)
    9.10 BLOOD SCREENING 
           9.10.1 RISING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET
                     TABLE 76 MARKET FOR BLOOD SCREENING, BY REGION,  2021–2028 (USD MILLION)
    9.11 NEWBORN SCREENING 
           9.11.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET
                     TABLE 77 KEY PRODUCTS FOR NEWBORN SCREENING
                     TABLE 78 MARKET FOR NEWBORN SCREENING, BY REGION,  2021–2028 (USD MILLION)
    9.12 OTHER APPLICATIONS 
           TABLE 79 MARKET FOR OTHER APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
 
10 IMMUNOASSAY MARKET TRENDS, BY END USER (Page No. - 158)
     10.1 INTRODUCTION 
             TABLE 80 IMMUNOASSAY INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 HOSPITALS & CLINICS 
             10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUME TO DRIVE MARKET
                        TABLE 81 IMMUNOASSAY MARKET SHARE FOR HOSPITALS & CLINICS, BY REGION,  2021–2028 (USD MILLION)
     10.3 CLINICAL LABORATORIES 
             10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET
                        TABLE 82 MARKET FOR CLINICAL LABORATORIES, BY REGION,  2021–2028 (USD MILLION)
     10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 
             10.4.1 GROWING DRUG DISCOVERY AND INCREASING R&D INVESTMENTS TO DRIVE MARKET
                        TABLE 83 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
     10.5 HOME CARE SETTINGS 
             10.5.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO DRIVE MARKET
                        TABLE 84 IMMUNOASSAY ANALYZERS MARKET FOR HOME CARE SETTINGS, BY REGION,  2021–2028 (USD MILLION)
     10.6 BLOOD BANKS 
             10.6.1 RISING DEMAND FOR BLOOD AND INCREASING NUMBER OF ACCIDENTS TO DRIVE MARKET
                        TABLE 85 AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION)
     10.7 RESEARCH & ACADEMIC LABORATORIES 
             10.7.1 RISING NUMBER OF MEDICAL COLLEGES AND UNIVERSITIES TO DRIVE MARKET
                        TABLE 86 MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
 
11 IMMUNOASSAY MARKET, BY REGION (Page No. - 167)
     11.1 INTRODUCTION 
            TABLE 87 IMMUNOASSAY INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
            FIGURE 34 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
            TABLE 88 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
            TABLE 89 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
            TABLE 90 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
            TABLE 91 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
            TABLE 92 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
            TABLE 93 NORTH AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
            TABLE 94 NORTH AMERICA: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
            TABLE 95 NORTH AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
            TABLE 96 NORTH AMERICA: IMMUNOASSAY MARKET OVERVIEW, BY END USER, 2021–2028 (USD MILLION)
             11.2.1 NORTH AMERICA: RECESSION IMPACT
             11.2.2 US
                        11.2.2.1 High healthcare expenditure and growth in geriatric population to drive market
                                      TABLE 97 US: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 98 US: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 99 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 100 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 101 US: AUTOMATED IMMUNOASSAY ANALYZERS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 102 US: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 103 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 104 US: IMMUNOASSAY MARKET OVERVIEW, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Increasing government support and rising incidence of chronic diseases to drive market
                                      TABLE 105 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 106 CANADA: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 107 CANADA: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 108 CANADA: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 109 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 110 CANADA: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 111 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 112 CANADA: IMMUNOASSAY MARKET OVERVIEW, BY END USER, 2021–2028 (USD MILLION)
     11.3 EUROPE 
            TABLE 113 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
            TABLE 114 EUROPE: AUTOMATED IMMUNOASSAY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
            TABLE 115 EUROPE: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
            TABLE 116 EUROPE: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
            TABLE 117 EUROPE: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
            TABLE 118 EUROPE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
            TABLE 119 EUROPE: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
            TABLE 120 EUROPE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
            TABLE 121 EUROPE: IMMUNOASSAY MARKET OVERVIEW, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 EUROPE: RECESSION IMPACT
             11.3.2 GERMANY
                        11.3.2.1 Germany to dominate European immunoassay market during forecast period
                                      TABLE 122 GERMANY: IMMUNOASSAY MARKET PREDICTION, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 123 GERMANY: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 124 GERMANY: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 125 GERMANY: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 126 GERMANY: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 127 GERMANY: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 128 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 129 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 ITALY
                        11.3.3.1 Growing geriatric population and increasing support for research to drive market
                                      TABLE 130 ITALY: IMMUNOASSAY MARKET PREDICTION, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 131 ITALY: AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 132 ITALY: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 133 ITALY: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 134 ITALY: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 135 ITALY: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 136 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 137 ITALY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 FRANCE
                        11.3.4.1 Rising use of POC testing and favorable reimbursement policies to drive market
                                      TABLE 138 FRANCE: IMMUNOASSAY MARKET PREDICTION, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 139 FRANCE: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 140 FRANCE: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 141 FRANCE: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 142 FRANCE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 143 FRANCE: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 144 FRANCE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 145 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to drive market
                                      TABLE 146 SPAIN: IMMUNOASSAY MARKET PREDICTION, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 147 SPAIN: AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 148 SPAIN: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 149 SPAIN: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 150 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 151 SPAIN: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 152 SPAIN: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 153 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.6 UK
                        11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market
                                      TABLE 154 UK: IMMUNOASSAY MARKET PREDICTION, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 155 UK: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 156 UK: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 157 UK: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 158 UK: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 159 UK: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 160 UK: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 161 UK: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.7 RUSSIA
                        11.3.7.1 Lack of reimbursement and delays in approval to limit market
                                      TABLE 162 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 163 RUSSIA: AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 164 RUSSIA: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 165 RUSSIA: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 166 RUSSIA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 167 RUSSIA: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 168 RUSSIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 169 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.8 REST OF EUROPE
                        TABLE 170 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 171 REST OF EUROPE: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 172 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 173 REST OF EUROPE: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                        TABLE 174 REST OF EUROPE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 175 REST OF EUROPE: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                        TABLE 176 REST OF EUROPE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 177 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
     11.4 ASIA PACIFIC 
             FIGURE 35 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
            TABLE 178 ASIA PACIFIC: AUTOMATED IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
            TABLE 179 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
            TABLE 180 ASIA PACIFIC: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
            TABLE 181 ASIA PACIFIC: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
            TABLE 182 ASIA PACIFIC: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
            TABLE 183 ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
            TABLE 184 ASIA PACIFIC: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
            TABLE 185 ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
            TABLE 186 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
             11.4.2 JAPAN
                        11.4.2.1 Increasing investments in healthcare technologies and research activities to drive market
                                      TABLE 187 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 188 JAPAN: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 189 JAPAN: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 190 JAPAN: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 191 JAPAN: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 192 JAPAN: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 193 JAPAN: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 194 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 CHINA
                        11.4.3.1 Increasing government investment and rising geriatric population to drive market
                                      TABLE 195 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 196 CHINA: AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 197 CHINA: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 198 CHINA: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 199 CHINA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 200 CHINA: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 201 CHINA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 202 CHINA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 INDIA
                        11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market
                                      TABLE 203 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 204 INDIA: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 205 INDIA: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 206 INDIA: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 207 INDIA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 208 INDIA: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 209 INDIA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 210 INDIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 AUSTRALIA
                        11.4.5.1 Increasing incidence of cancer and rising blood donations to drive market
                                      TABLE 211 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 212 AUSTRALIA: AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 213 AUSTRALIA: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 214 AUSTRALIA: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 215 AUSTRALIA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 216 AUSTRALIA: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 217 AUSTRALIA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 218 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.6 SOUTH KOREA
                        11.4.6.1 Rising healthcare spending and investments in research to drive market
                                      TABLE 219 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 220 SOUTH KOREA: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 221 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 222 SOUTH KOREA: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 223 SOUTH KOREA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 224 SOUTH KOREA: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 225 SOUTH KOREA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 226 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.7 INDONESIA
                        11.4.7.1 Increasing geriatric population and favorable government healthcare policies to drive market
                                      TABLE 227 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 228 INDONESIA: AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 229 INDONESIA: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 230 INDONESIA: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 231 INDONESIA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 232 INDONESIA: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 233 INDONESIA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 234 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.8 REST OF ASIA PACIFIC
                        TABLE 235 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 236 REST OF ASIA PACIFIC: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 237 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 238 REST OF ASIA PACIFIC: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                        TABLE 239 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 240 REST OF ASIA PACIFIC: MARKET, BY SPECIMEN,  2021–2028 (USD MILLION)
                        TABLE 241 REST OF ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 242 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER,  2021–2028 (USD MILLION)
     11.5 LATIN AMERICA 
            TABLE 243 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
            TABLE 244 LATIN AMERICA: AUTOMATED IMMUNOASSAY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
            TABLE 245 LATIN AMERICA: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
            TABLE 246 LATIN AMERICA: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
            TABLE 247 LATIN AMERICA: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
            TABLE 248 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
            TABLE 249 LATIN AMERICA: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
            TABLE 250 LATIN AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
            TABLE 251 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.1 LATIN AMERICA: RECESSION IMPACT
             11.5.2 BRAZIL
                        11.5.2.1 Brazil commanded largest share in Latin American immunoassay market in 2022
                                      TABLE 252 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 253 BRAZIL: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 254 BRAZIL: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 255 BRAZIL: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 256 BRAZIL: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 257 BRAZIL: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 258 BRAZIL: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 259 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.3 MEXICO
                        11.5.3.1 Increasing geriatric population and rising medical tourism to drive market
                                      TABLE 260 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 261 MEXICO: AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 262 MEXICO: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 263 MEXICO: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                                      TABLE 264 MEXICO: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 265 MEXICO: MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)
                                      TABLE 266 MEXICO: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 267 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.4 REST OF LATIN AMERICA
                        TABLE 268 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 269 REST OF LATIN AMERICA: MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 270 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 271 REST OF LATIN AMERICA: MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)
                        TABLE 272 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 273 REST OF LATIN AMERICA: MARKET, BY SPECIMEN,  2021–2028 (USD MILLION)
                        TABLE 274 REST OF LATIN AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 275 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER,  2021–2028 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH
             11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 276 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 277 MIDDLE EAST & AFRICA: AUTOMATED IMMUNOASSAY ANALYZERS MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 278 MIDDLE EAST & AFRICA: MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 279 MIDDLE EAST & AFRICA: MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)
                        TABLE 280 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 281 MIDDLE EAST & AFRICA: MARKET, BY SPECIMEN,  2021–2028 (USD MILLION)
                        TABLE 282 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 283 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER,  2021–2028 (USD MILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 291)
     12.1 OVERVIEW 
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
                       TABLE 284 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET
     12.3 REVENUE ANALYSIS 
             FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS
     12.4 MARKET SHARE ANALYSIS 
             TABLE 285 DEGREE OF COMPETITION IN IMMUNOASSAY INDUSTRY
             FIGURE 37 IMMUNOASSAY INDUSTRY SHARE, BY KEY PLAYER (2022)
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 38 COMPANY EVALUATION MATRIX, 2022
             12.5.5 COMPANY FOOTPRINT
                        TABLE 286 OVERALL FOOTPRINT
                        TABLE 287 PRODUCT FOOTPRINT
                        TABLE 288 REGIONAL FOOTPRINT
     12.6 START-UP/SME EVALUATION MATRIX 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 RESPONSIVE COMPANIES
             12.6.3 DYNAMIC COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 39 START-UP/SME EVALUATION MATRIX, 2022
             12.6.5 COMPETITIVE BENCHMARKING
                        TABLE 289 KEY START-UPS/SMES IN IMMUNOASSAY MARKET
     12.7 COMPETITIVE SCENARIOS AND TRENDS 
             12.7.1 KEY PRODUCT LAUNCHES AND APPROVALS
                        TABLE 290 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–SEPTEMBER 2023
             12.7.2 KEY DEALS
                        TABLE 291 KEY DEALS, JANUARY 2020–SEPTEMBER 2023
             12.7.3 OTHER KEY DEVELOPMENTS
                        TABLE 292 OTHER KEY DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2023
 
13 COMPANY PROFILES (Page No. - 305)
     13.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             13.1.1 ABBOTT LABORATORIES
                        TABLE 293 ABBOTT LABORATORIES: COMPANY OVERVIEW
                        FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
             13.1.2 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 294 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             13.1.3 SIEMENS HEALTHINEERS AG
                        TABLE 295 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
                        FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
             13.1.4 DANAHER CORPORATION
                        TABLE 296 DANAHER CORPORATION: COMPANY OVERVIEW
                        FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.5 THERMO FISHER SCIENTIFIC INC.
                        TABLE 297 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             13.1.6 REVVITY
                        TABLE 298 REVVITY: COMPANY OVERVIEW
                        FIGURE 45 REVVITY: COMPANY SNAPSHOT (2022)
             13.1.7 BECTON, DICKINSON AND COMPANY
                        TABLE 299 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
                        FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
             13.1.8 DIASORIN S.P.A.
                        TABLE 300 DIASORIN S.P.A.: COMPANY OVERVIEW
                        FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
             13.1.9 BIO-RAD LABORATORIES, INC.
                        TABLE 301 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
                        FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             13.1.10 QUIDELORTHO CORPORATION
                                                TABLE 302 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
                        FIGURE 49 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.11 BIOMÉRIEUX
                        TABLE 303 BIOMÉRIEUX: COMPANY OVERVIEW
                        FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2022)
             13.1.12 QIAGEN N.V.
                        TABLE 304 QIAGEN N.V.: COMPANY OVERVIEW
                        FIGURE 51 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
             13.1.13 SYSMEX CORPORATION
                        TABLE 305 SYSMEX CORPORATION: COMPANY OVERVIEW
                        FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.14 AGILENT TECHNOLOGIES, INC.
                        TABLE 306 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
                        FIGURE 53 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
             13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
                        TABLE 307 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
                        FIGURE 54 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)
     13.2 OTHER PLAYERS 
             13.2.1 MERCK KGAA
             13.2.2 MERIDIAN BIOSCIENCE
             13.2.3 BIO-TECHNE
             13.2.4 CELLABS
             13.2.5 ABNOVA CORPORATION
             13.2.6 J. MITRA & CO. PVT. LTD.
             13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCE)
             13.2.8 CELL SCIENCES
             13.2.9 ENZO BIOCHEM
             13.2.10 CREATIVE DIAGNOSTICS
             13.2.11 BOSTER BIOLOGICAL TECHNOLOGY
             13.2.12 ELABSCIENCE
             13.2.13 WAK-CHEMIE MEDICAL
             13.2.14 SERACARE LIFESCIENCES INC.
             13.2.15 EPITOPE DIAGNOSTICS
             13.2.16 KAMIYA BIOMEDICAL COMPANY
             13.2.17 GYROS PROTEIN TECHNOLOGIES
             13.2.18 TRIVITRON HEALTHCARE
             13.2.19 INBIOS INTERNATIONAL, INC.
             13.2.20 MACCURA BIOTECHNOLOGY CO., LTD.
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 384)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS

The objective of the study is to analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as product launches and approvals, expansions, and partnerships of the leading players, the competitive landscape of the immunoassay market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the immunoassay market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was conducted after acquiring knowledge about the immunoassay market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as doctors, nurses, and hospital purchase managers) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

Breakdown of Primary Participants:

Immunoassay Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers are defined based on a company’s total revenue. As of 2022: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Thermo Fisher Scientific Inc. (US)

Product Manager

Abbott Laboratories (US)

VP Sales

Siemens Healthineers AG (Germany)

Regional Sales Head

Danaher Corporation (US)

Sales Director

Market Size Estimation

All major product manufacturers offering various immunoassays were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value immunoassays market was also split into various segments and subsegments at the region and country level based on:

  • Product mapping of various manufacturers for each type of immunoassay products at the regional and country level
  • Relative adoption pattern of each product type among key application segments at the regional and/or country-level
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level

Global Immunoassays Market Size: Bottom Up Approach

Immunoassay Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Immunoassays Market Size: Top Down Approach

Immunoassay Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the immunoassays industry.

Market Definition

An immunoassay is a test that is based on biochemistry to quantify the presence or concentration of an analyte. An analyte can be a large protein or antibody produced due to an infection. Immunoassays have become popular and well-established procedures in laboratories. They quickly and easily provide precise and accurate results. This technique is mostly used in clinical diagnostics, drug monitoring, drug discovery, and food testing.

Key Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To define, describe, segment, and forecast the immunoassays market by product, technology, specimen, application, and end user, and region
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall immunoassay market
  • To forecast the size of the immunoassays market in five main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific Middle East & Africa, and Latin America.
  • To profile key players in the immunoassays market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments, such as product launches and approvals; expansions; and partnerships; of the leading players in the immunoassays market
  • To benchmark players within the immunoassays market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the immunoassay market into specific countries/regions in the Rest of Europe, Rest of Asia Pacific, and Rest of the World.

Company Information

  • Detailed analysis and profiling of additional market players (up to 3)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 4751
Published ON
Oct, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Immunoassay Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback